- M.D., University of Connecticut School of Medicine, Farmington, CT
- B.S., Biology, with distinction, McGill University, Montreal, Quebec, Canada
- Internship/Residency, Pediatrics, University of Vermont, Burlington, VT
- Fellowship, Pediatric Pulmonology, Children's Hospital, Boston, MA
BIO
Thomas Lahiri is a Professor of Pediatrics at the University of Vermont Larner College of Medicine. He also serves as the Medical Director for the Division of Pediatric Pulmonology and the Cystic Fibrosis Center Director at the Golisano Children's Hospital at University of Vermont Health. He has been involved in guideline development for the Cystic Fibrosis Foundation. His clinical and research interests include the treatment of cystic fibrosis and airway disorders.
Courses
- First Patient (Orientation)
- Cardiovascular Respiratory Renal (Pediatric Pulmonology)
Awards and Achievements
- 1995 UVM Medical Student Teaching Award for Pediatrics clerkship
- 1997 Genentech Resident Fellowship Award
- 2002 Ethan Sims Clinical Research Feasibility Fund
- 2003 UVM Pediatric Resident Teaching Award
- 2009 Cystic Fibrosis Foundation Quality Care Award
- 2011 CHEST Foundation D. Robert McCaffree Humanitarian Award
- 2012-13 U.S.News & World Report Designation as Best Children’s Hospital for Pulmonology
- 2013 UVM Pediatric Resident Teaching Award
- 2014 UVM Pediatric Resident Teaching Award
- 2014 Cystic Fibrosis Foundation Quality Care Award
- 2014 University of Vermont Medical Center GME Teacher of the Year
- 2019 Cystic Fibrosis Foundation Quality Care Award
- 2024 Nominated, University of Vermont LCOM Educator of the Year
- 2025 Cystic Fibrosis Foundation Outstanding Partnership Award
Bio
Thomas Lahiri is a Professor of Pediatrics at the University of Vermont Larner College of Medicine. He also serves as the Medical Director for the Division of Pediatric Pulmonology and the Cystic Fibrosis Center Director at the Golisano Children's Hospital at University of Vermont Health. He has been involved in guideline development for the Cystic Fibrosis Foundation. His clinical and research interests include the treatment of cystic fibrosis and airway disorders.
Courses
- First Patient (Orientation)
- Cardiovascular Respiratory Renal (Pediatric Pulmonology)
Awards and Achievements
- 1995 UVM Medical Student Teaching Award for Pediatrics clerkship
- 1997 Genentech Resident Fellowship Award
- 2002 Ethan Sims Clinical Research Feasibility Fund
- 2003 UVM Pediatric Resident Teaching Award
- 2009 Cystic Fibrosis Foundation Quality Care Award
- 2011 CHEST Foundation D. Robert McCaffree Humanitarian Award
- 2012-13 U.S.News & World Report Designation as Best Children’s Hospital for Pulmonology
- 2013 UVM Pediatric Resident Teaching Award
- 2014 UVM Pediatric Resident Teaching Award
- 2014 Cystic Fibrosis Foundation Quality Care Award
- 2014 University of Vermont Medical Center GME Teacher of the Year
- 2019 Cystic Fibrosis Foundation Quality Care Award
- 2024 Nominated, University of Vermont LCOM Educator of the Year
- 2025 Cystic Fibrosis Foundation Outstanding Partnership Award
Select Publications
- Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. Pediatrics 2016 : 137(4): e20151784. PMID 27009033
- Lahiri T, Guillet A, Diehl S, Ferguson MA. High dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. Pediatr Pulmonol 2014: 49:148-53. PMID 23532925
- Nelson BA, Boyer D, Lahiri T, Oermann CM, Rama J. A statement on the current status and future needs of the pediatric pulmonology workforce: Pipeline Workgroup. Pediatr Pulmonol 2020. Doi: 10.1002/ppul.25139. PMID: 33107699
- Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2022: 57 Suppl 1:S60-74. doi: 10.1002/ppul.25660. PMID 34473419
- Green DM, Lahiri T, Raraigh KS, Ruiz F, Spano J, Antos N, Bonitz L, Christon L, Gregoire-Bottex M, Hale J, Langfelder-Schwind E, La Parra Perez A, Maguiness K, Massie J, McElroy-Barker E, McGarry M, Mercier A, Munck A, Oliver K, Self S, Singh K, Smiley M, Snodgrass S, Tluczek A, Tuley P, Lomas P, Wong E, Hempstead SE, Faro A, Ren CL. Cystic Fibrosis Foundation evidence-based guidelines for the management of cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis. Pediatrics 2024:153(5):e2023064657. PMID: 38577740